RIMSO-50 (dimethyl sulfoxide) by Viatris (2) is pharmacology fluocinolone acetonide is chemically related to prednisolone and possesses marked anti-inflammatory properties when applied topically. First approved in 1978.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
RIMSO-50 (dimethyl sulfoxide) is an intravesical solution approved in 1978 for interstitial cystitis and related bladder conditions. It works by reducing inflammation, edema, and pain in the bladder mucosa, and enhances percutaneous absorption of other therapeutic agents including steroids and vasoconstrictors. The drug has demonstrated anti-inflammatory activity and improves urinary symptoms in patients with bladder inflammation.
Mature product with limited spending and claim volume suggests small, stable commercial team focused on retention rather than expansion.
PHARMACOLOGY Fluocinolone acetonide is chemically related to prednisolone and possesses marked anti-inflammatory properties when applied topically. It has been shown to have over 100 times the anti-inflammatory activity of hydrocortisone. Fluocinolone acetonide decreases edema, inflammation,…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on RIMSO-50 at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Viatris (2) is hiring 1 role related to this product
Working on RIMSO-50 offers exposure to niche specialty care marketing and supply chain management in a mature product portfolio. Career growth is limited but provides stability and deep expertise in a specialized therapeutic area.
1 open roles linked to this drug
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo